Vitality Watch

Dossier clinicaltrials trial early 16-sep-2026
Small or early-phase human trial or pilot study

RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients

Key claim: A pragmatic randomized, double-blind, active-controlled trial will test whether RANKL inhibition treats sarcopenia in patients with hip fracture.

Abstract

The objective of this study is to conduct a pragmatic, randomized, double-blind, active-controlled trial to assess the efficacy of receptor activator of nuclear factor-kB ligand (RANKL) inhibition in the treatment of sarcopenia in hip fractures.

Why this matters

Sarcopenia intervention research has been dominated by resistance training plus nutrition, with pharmacologic candidates mostly at the mechanism or repurposing stage. A pragmatic double-blind RCT testing a RANKL-pathway drug specifically for sarcopenia in hip fracture patients puts a bone-axis therapy into a muscle endpoint in exactly the acute frail-surgical population where both bone and muscle collapse together. Protocol-only for now — the interpretive question is whether shared osteo-muscular biology yields functional gains beyond bone protection.

Source

Link

Briefing card

RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients
Stage: trial early · clinicaltrials · 16-sep-2026

If you or a family member are prescribed a RANKL inhibitor after a hip fracture, a muscle-preservation indication is being formally tested but has not yet been shown.

A pragmatic randomized, double-blind, active-controlled trial will test whether RANKL inhibition treats sarcopenia in patients with hip fracture.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT07056478

build build 880 · 2bcef25 · 2026-11-18